London · Seed–Late Stage · 11 people tracked
Also known as MVM PARTNERS LLP · MVM PARTNERS, LLC
Find your way into MVM Life Science Partners
2,532 people in our graph share verified history with the MVM Life Science Partners team — schools, employers, funds. One of them is your warm intro.
Investment thesis
MVM invests broadly across healthcare and life sciences, including medical technology, pharmaceuticals, diagnostics, digital health, health IT, life science tools, and contract research and manufacturing. It provides equity to companies with high growth potential that address significant unmet needs in large addressable markets, prioritizing differentiated technologies with durable competitive protection through IP, market-entry barriers, statutory exclusivity, or unique branding. MVM partners closely with best-in-class management teams to accelerate growth, drive strategic acquisitions, and establish new standards of care. It maintains a concentrated portfolio and typically deploys $20-100 million per company over the holding period.
Source: firm website, verified Sep 15, 2026.
Team · 11 people
from public directories
What they invest in
from 15 of 16 portfolio companiesHealthtech ×13Medical Devices ×8Biotech ×6Hardware ×3
HQs:United States×13Ireland×1
Investments · 16 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12023 · 12022 · 12021 · 22020 · 12017 · 12016 · 22015 · 112 dated
BioProtect develops a balloon spacer device for brachytherapy procedures, used to create spacing during cancer radiation treatment.
BiotechHealthtechMedical Devices
Itay Barnea(Chief Executive Officer)inDerek Webster(Chief Commercial Officer)inLee Adler(Chief Operating Officer)inShahar Shaked(Chief Financial Officer)inDafna Carmi-Yinon(Chief Product and Clinical Officer)in
Co-investorsAlmeda VenturesTriventuresOlympus Innovation VenturesPeregrine VenturesXenia Venture Capital
AccuVein manufactures vein visualization systems for medical professionals to locate veins during procedures.
HardwareHealthtechMedical DevicesCold Spring Harbor, US
Ron Goldman(Executive Officer, Director)inChris Hutchison(President & CEO)in
BoardJames Lackie(Director)Eric Bednarski(Director)Frank Flaut III(Director)Christopher Gabrieli(Director)
Board seatStephen ReedersAkhilesh Pathipati· per SEC Form D
Co-investorsBessemer Venture Partners
CurvaFix develops the CurvaFix Low Profile intramedullary nailing system, curved implants for surgical stabilization of pelvic fractures.
HardwareHealthtechMedical DevicesBellevue, US
Jeffrey Poole(Executive Officer)Mark Foster(Executive Officer, Director)inSteven Dimmer(Executive Officer, Director, Promoter)Dong-Gun Kim(Director)
Board seatJack TanakaEric Fritz· per SEC Form D
Co-investorsAlliance of AngelsRockies Venture ClubSPRINGROCK VENTURESSwan Venture FundKeiretsu CapitalSectoral Asset Management+1 more
Optinose is a specialty pharmaceutical company that develops and markets products for patients with conditions treated by ear, nose, and throat (ENT) and allergy specialists.
BiotechHealthtechMedical DevicesYardley, US
Per Djupesland(Executive Officer, Director)inMichele Janis(Executive Officer)Peter Miller(Executive Officer, Director)inTerrence Terifay(Executive Officer)Ramy Mahmoud(Executive Officer)in
BoardKlaas De Boer(Director)
Board seatEric BednarskiKyle Dempsey· per SEC Form D · $4.7M raise · filed May 2024
Co-investorsForesite Capital
Tarsa Therapeutics developed TBRIA, an oral formulation of calcitonin for treating postmenopausal osteoporosis in women more than five years post menopause when other treatments are unsuitable.
BiotechPhiladelphia, US
David Brand(Executive Officer, Director)inGregory Lumpkin(Executive Officer)
BoardRichard Kollender(Director)Martin Edwards(Director)Derek Ferguson(Director)
Board seatEric Bednarski· per SEC Form D
Co-investorsForesite CapitalOxford Finance LLCQuaker BioVentures
HealthtechCampbell, US
Nersi Nazari(Executive Officer, Director)inSteve Zadig(Executive Officer, Director)in
BoardRichard Feachem(Director)Tom Saunders(Director)
Board seatStephen Reeders· per SEC Form D · $38.1M raise · filed Oct 2017
Co-investorsAsahi Kasei Corporate Venture CapitalEssex Woodlands Healthcare PartnersRevelation PartnersAlly Bridge GroupTrinity Capital
Biotheranostics develops proprietary genomic assays used to support personalized disease management in oncology.
BiotechHealthtechMedical DevicesSan Diego, US
Nicholas Barthelemy(Executive Officer, Director, Promoter)
BoardDavid Kabakoff(Director)inEric Bednarski(Director)Alejandro Sanchez(Director)in
Co-investorsEvidity Health CapitalHealthQuest Capital
Leader in non-invasive cardiac output and hemodynamic monitoring with its CHEETAH NICOM system; based in Newton, MA with offices in Tel-Aviv and Portland.
HealthtechNewton, US
Christopher Hutchison(Executive Officer, Director)inKevin McArdle(Executive Officer)Yuval Rozen(Executive Officer)
BoardSteven Reeders(Director)Renard Charity(Director)inAnthony Moshal(Director)
Co-investorsAscension VenturesHighCape CapitalRobert Bosch Venture Capital
ProVerum is a venture-backed medical device startup developing minimally invasive technologies to treat benign prostatic hyperplasia (BPH).
HardwareHealthtechMedical DevicesDublin, IE
Dr Conor Harkin(Founder)inRíona Ní Ghriallais(Founder)in
Co-investorsAtlantic Bridge VenturesLightstone VenturesOrbiMedIreland Strategic Investment Fund
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Co-investorsBlackRockEndeavour VisionRTW Investments L.P.Soleus CapitalvenBio Global StrategicVivo Capital
Urotronic develops drug-coated balloons for interventional urology, including the Optilume products for treating benign prostatic hyperplasia (BPH) and urethral strictures.
HealthtechMedical DevicesPlymouth, US
Junfeng Wang(Director)David Perry(Executive Officer, Director)Tan Ching(Director)Hui Hu(Director, Promoter)Lixiao Wang(Director, Promoter)Doug Kohrs(Director)
Co-investorsHM Venture PartnersEnterprise IrelandGilde HealthcareIreland Strategic Investment FundLegend CapitalLightstone Ventures+1 more
VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings.
BiotechHealthtechMedical Devices
Co-investorsBrace PharmaRunway Growth Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
eyeBrain MedicalZipline MedicalGT Medical TechnologiesVertos Medical
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
Vital Connect · stocktitan.net · Aug 6, 2026
ProVerum · siliconcanals.com · Aug 30, 2025
Urotronic · fiercebiotech.com · Aug 26, 2025
Frequently asked questions
- How many investments has MVM Life Science Partners made?
- MVM Life Science Partners has 16 tracked investments, including 2 dated in the last 24 months.
- What stage does MVM Life Science Partners invest at?
- MVM Life Science Partners invests at the Seed, Series A, Growth, Late Stage stages.
- What is MVM Life Science Partners's typical check size?
- MVM Life Science Partners typically writes checks of $20M – $100M.
- What sectors does MVM Life Science Partners focus on?
- MVM Life Science Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is MVM Life Science Partners located?
- MVM Life Science Partners is headquartered in London, GB.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm founded by Vinod Khosla.